Mini-dose MTX Plus Standard-dose Steroid for the Initial Treatment of Acute GVHD
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This trial is a randomized (1:1) phase III open label study of frontline mini-MTX plus
methylprednisolone 2mg/kg/day compared to methylprednisolone 2mg/kg in allogeneic stem cell
transplant recipients with grade 2-4 aGVHD.